ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension

    Not Recruiting
  • End date
    Dec 18, 2023
  • participants needed
  • sponsor
    Aadi, LLC
Updated on 14 September 2022
pulmonary function test
primary pulmonary hypertension
congenital heart defects
pulmonary arterial hypertension
left ventricular end-diastolic pressure


mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

Condition Pulmonary Hypertension
Treatment ABI-009, nab-rapamycin, albumin-bound rapamycin
Clinical Study IdentifierNCT02587325
SponsorAadi, LLC
Last Modified on14 September 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note